The study team used baseline plasma from deeply phenotyped participants enrolled in the Parkinson's Precision Medicine Initiative (PPMI). The dataset comprised 523 people with early, sporadic Parkinson's disease (diagnosed <2 years) who were positive on a CSF aSyn-SAA assay, and 97 healthy controls (HC) with negative aSyn-SAA. Plasma assays included P-tau217 (Roche Diagnostics), neurofilament light chain (NfL, Quanterix), and glial fibrillary acidic protein (GFAP, Quanterix). Amyloid-beta peptides (Aβ40 and Aβ42, C2N Diagnostics) were measured in the PD group only. The investigators framed the work as an effort to link peripheral neurodegeneration signals to subsequent clinical progression.
Median and interquartile ranges for the measured analytes were reported in the abstract. For P-tau217, HC median 0.14 pg/mL [0.06–0.75] and PD median 0.15 pg/mL [0.06–0.90]. For NfL, HC median 10.6 pg/mL [3.13–49.85] and PD median 12.26 pg/mL [3.77–62.67]. For GFAP, HC median 66.56 pg/mL [19.75–403.48] and PD median 87.19 pg/mL [14.55–531.82]. Reported PD amyloid values were Aβ40 median 391.32 pg/mL [209.95–538.38] and Aβ42 median 42.74 pg/mL [27.75–68.55]. The study team observed that none of the biomarkers differed significantly between HC and PD at baseline. They also reported that biomarker concentrations in PD correlated with age.
The authors reported that higher baseline P-tau217 and NfL were associated with increased hazards of subsequent worse cognitive outcomes in the PD group. Models adjusted for age, sex, and the baseline value of the outcome variable were used to evaluate these relationships. The abstract does not include numerical hazard ratios, confidence intervals, or p-values; those details are not reported in the abstract and would require consulting the full text or supplementary data. Still, investigators stated that baseline plasma signals carried prognostic information for cognitive decline.
In addition to cognition, the study team found that higher baseline levels of P-tau217 and NfL were associated with greater hazards of a worse balance outcome among people with PD. The abstract identifies balance as a functional domain affected in association with the same plasma markers that predicted cognitive worsening. The methods note that models controlled for age, sex, and baseline outcome, but the abstract does not present the exact balance measure used, numerical effect sizes, or event counts.
Investigators reported that P-tau217, NfL, and GFAP were associated with change in cognitive scores over time. Follow-up extended up to 11 years for some participants. The analysis approach used longitudinal models that included baseline covariates; however, the abstract does not detail the cognitive instruments employed, the magnitude of score change per biomarker tertile, or model coefficients. The statement in the abstract suggests a consistent relationship across multiple neurodegeneration biomarkers and cognitive trajectory in early PD with confirmed synucleinopathy.
The cohort selection required PD participants to be early in disease course (<2 years since diagnosis) and to have positive CSF aSyn-SAA; controls were aSyn-SAA negative. Biomarker assays came from specified commercial platforms: Roche for P-tau217, Quanterix for NfL and GFAP, and C2N Diagnostics for Aβ measurements. The analytic models controlled for age, sex, and baseline outcome variables. The abstract indicates follow-up data were available for up to 11 years, allowing assessment of longer-term clinical trajectories.
The abstract reports associations but does not provide detailed statistical parameters (for example, hazard ratios, confidence intervals, p-values, or sample sizes for specific outcomes) in this summary; those results are not included in the abstract text and must be retrieved from the full manuscript or supplementary materials. The abstract also does not specify which cognitive or balance instruments were analyzed, nor does it detail how amyloid measures in PD were incorporated into the prognostic models. Finally, because this is a preprint, the work has not undergone peer review; investigators and readers should interpret findings accordingly. Future steps documented implicitly by the report include examination of full statistical tables, replication in independent cohorts, and peer-review validation.